blood pressure heart and kidney disease · reviewed 2026-08-01
Captopril and jararaca venom: a venom peptide became an enzyme-design clue
A peptide from Bothrops jararaca venom helped reveal angiotensin-converting enzyme as a blood-pressure target. Captopril is a small, fully synthetic molecule designed from that biochemical clue; it is not diluted venom and venom contains no captopril.
Defined medicine
captopril
ACE inhibitor · angiotensin-converting-enzyme inhibitor
Where it came from
Captopril was rationally designed as an orally active, nonpeptide ACE inhibitor after venom-derived peptide inhibitors helped define the target and active-site requirements. Its proline-based small-molecule structure is synthetic. ondetti-captopril-1977 dailymed-captopril
What it is trying to achieve
Captopril has labelled uses in hypertension, heart failure, selected left-ventricular dysfunction after myocardial infarction, and specified diabetic nephropathy. Each use has clinical conditions beyond simple blood-pressure lowering. dailymed-captopril
How it acts
Captopril competitively inhibits ACE, reducing conversion of angiotensin I to vasoconstrictor angiotensin II and reducing aldosterone signalling while also affecting bradykinin breakdown. dailymed-captopril ondetti-captopril-1977
Why people developed this form
The design programme translated a potent but peptide-based enzyme clue into a small, selective inhibitor active by mouth, with a defined structure suitable for chronic clinical study. ondetti-captopril-1977 dailymed-captopril
Present form and manufacture
Regulated captopril tablets contain a declared small molecule and strength. They are chemically and clinically separate from purified venom peptide, crude venom, and other ACE inhibitors. dailymed-captopril
Bioavailability
Captopril is rapidly absorbed orally; food reduces absorption, and a substantial portion is eliminated through the kidneys. Renal function and interacting medicines can materially alter exposure and effect. dailymed-captopril
Its own risks
Major risks include fetal injury or death, angioedema, excessive hypotension, kidney dysfunction, high potassium, cough, proteinuria, rare severe neutropenia, and consequential drug interactions. dailymed-captopril
What nature offers
No link below is assumed to be equivalent. Each names the organism or tradition, exact preparation, measured exposure, human evidence, and replacement boundary separately.
Nature link · Historical discovery lead
purified jararaca-venom peptide design lead
Bothrops jararaca
venom-derived ACE-inhibiting peptide lead · bradykinin-potentiating peptide research
- Exact material
- Purified peptide material derived from Bothrops jararaca venom and used as an ACE-inhibition design lead, kept separate from crude venom and from the synthetic small-molecule candidates tested in the 1977 paper. ondetti-captopril-1977
- Relationship
- Historical discovery lead. Observation of a natural material or molecule helped reveal the drug family, without making the final medicine identical to the source.
Lineage
Venom-peptide research helped make ACE inhibition a drug-design clue. The 1977 paper reports that active-site modelling guided synthetic proline derivatives culminating in a chemically different oral inhibitor. ondetti-captopril-1977 dailymed-captopril
Human evidence
Preclinical only Evidence product match: no
The 1977 paper reports enzyme, isolated-tissue, and animal blood-pressure work for designed small molecules. It supplies no human clinical evidence for the peptide lead or crude venom and transfers no captopril outcomes to either material. ondetti-captopril-1977
Bioavailability and preparation
A purified peptide lead and oral captopril have different size, stability, absorption, and manufacture. Crude venom has no defined captopril exposure because captopril is absent from it. ondetti-captopril-1977 dailymed-captopril
Safety
WHO describes snakebite envenoming as an acute emergency that can cause fatal bleeding, paralysis, kidney failure, and severe tissue injury. The discovery value of a purified peptide offers no safe route from crude venom to treatment. who-snakebite ondetti-captopril-1977
Can it replace the medicine?
Jararaca venom supplied a target clue, not natural captopril and not a clinically usable alternative to an ACE-inhibitor medicine. ondetti-captopril-1977 dailymed-captopril
The honest comparison
The natural contribution is biochemical intelligence: a venom peptide exposed a controllable enzyme pathway. Captopril retains that target logic while changing the molecule into an oral synthetic drug. ondetti-captopril-1977 dailymed-captopril
This is nature-inspired design, not exact-molecule extraction. Respecting the lineage means crediting the venom peptide while keeping purified research material, crude venom, and captopril rigorously separate. ondetti-captopril-1977 dailymed-captopril
Sources for this card
- Design of specific inhibitors of angiotensin-converting enzyme Science · primary research · read 2026-08-01
- Captopril tablet prescribing information DailyMed · regulatory label · read 2026-08-01
- Snakebite envenoming fact sheet World Health Organization · official guidance · read 2026-08-01
Same card as data: /api/remedies/captopril-bothrops-venom.json. Found a source or claim problem? Open a correction.